biostudies-literatureGrivas PSpanish Society of Medical OncologyAmerican Cancer SocietyNCATS NIH HHSNCI NIH HHSProstate Cancer FoundationNIH787-800https://www.ebi.ac.uk/biostudies/studies/S-EPMC7972830biostudies-literatureUnknown32(6)<h4>Background</h4>Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID-19 and Cancer Consortium (CCC19) to identify prognostic clinical factors, including laboratory measurements and anticancer therapies.<h4>Patients and methods</h4>Patients with active or historical cancer and a laboratory-confirmed SARS-CoV-2 diagnosis recorded between 17 March and 18 November 2020 were included. The primary outcome was COVID-19 severity measured on an ordinal scale (uncomplicated, hospitalized, admitted to intensive care unit, mechanically ventilated, died within 30 days). Multivariable regression models included demograpAnnals of oncology : official journal of the European Society for Medical OncologyAssociation of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.PMC7972830T32 CA009515UL1 TR001873P30 CA046592UG1 CA190140P30 CA056036P30 CA054174P30 CA015704UL1 TR001425UL1 TR000445P30 CA168524P30 CA013696P30 CA177558P30 CA046934P30 CA016058P30 CA013330P30 CA196521UG1 CA189974P30 CA068485P30 CA240139T32 CA236621U01 CA231840P30 CA023100UG1 CA189859Nock NLTucker MDBernicker EHMico VRosovsky RPSchmidt ALThompson MAFecher LAPuc MDixon BPeddi PSalazar MZubiri LLopes GFazio AJani CMenon HBakouny ZChism DDGlover MJThakkar AHuynh-Le MWulff-Burchfield EBilen MAReeves MEShah SAKhaki ARDesai ASmits MWarner JLTadesse ECurran CStreckfuss MShah MRGill DMLammers PEWu JTKoshkin VSBishnoi RHalfdanarson TRLi ARubinstein SMAcoba JDLyman GHGupta SHsu EFarmakiotis DWise-Draper TMRavindranathan DMishra SHalabi SCabal AZhu HJohnson DBGulati SBerg SHalmos BVinh DCNagaraj GShah DPFu JMundt DYu PPStover DGGrivas PKwon DHBashir BPeters SPiper-Vallillo AJHawley JEBouganim NShyr YMesa RAGoyal SGadgeel SMElkrief ARosenstein LZhou AYPatel KGBekaii-Saab TDurbin EBShaya JABindal PCaimi PFXie ZRivera DRSchwartz GKHennessy CStockerl-Goldstein KELi XFriese CRDoroshow DBReuben DYVerma AKPark CHausrath DJMcKay RRSingh SRKTachiki LNakayama JLoaiza-Bonilla ALow CAKuderer NMHsu CYAbidi MZPainter CANakasone ESJayaraj AGrover PWeiss MLustberg MBBowles DWKasi ACrowell JSubbiah SChoueiri TKGalsky MDKhan HMcNair CFrench BZhang TPatel JMHwang CFlora DBShah CNizam APennell NARini BIfalseAssociation of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.<h4>Background</h4>Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID-19 and Cancer Consortium (CCC19) to identify prognostic clinical factors, including laboratory measurements and anticancer therapies.<h4>Patients and methods</h4>Patients with active or historical cancer and a laboratory-confirmed SARS-CoV-2 diagnosis recorded between 17 March and 18 November 2020 were included. The primary outcome was COVID-19 severity measured on an ordinal scale (uncomplicated, hospitalized, admitted to intensive care unit, mechanically ventilated, died within 30 days). Multivariable regression models included demograp2021-01-01T00:00:00Z2021 Jun2026-05-01T16:25:25.185Z2022-02-11T08:43:49.263ZS-EPMC79728303374604710.1016/j.annonc.2021.02.024